| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-339 in Healthy Volunteers (NCT07748702) | Chong Kun Dang Pharmaceutical | 2026-08-20 |
| Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT07532148) | Chong Kun Dang Pharmaceutical | 2026-06-01 |
| A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer (NCT07439094) | Chong Kun Dang Pharmaceutical | 2026-04-16 |
| Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients (NCT07365358) | Chong Kun Dang Pharmaceutical | 2026-03-01 |
| A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846 (NCT07404735) | Chong Kun Dang Pharmaceutical | 2026-02-23 |
| Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants (NCT07258745) | Chong Kun Dang Pharmaceutical | 2025-11-26 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers (NCT07304726) | Chong Kun Dang Pharmaceutical | 2025-10-30 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers (NCT07304700) | Chong Kun Dang Pharmaceutical | 2025-10-28 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers (NCT07304687) | Chong Kun Dang Pharmaceutical | 2025-10-24 |
| Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors (NCT07215637) | Chong Kun Dang Pharmaceutical | 2025-10-16 |
| Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea (NCT06942156) | Chong Kun Dang Pharmaceutical | 2025-08-14 |
| A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants (NCT06979973) | Chong Kun Dang Pharmaceutical | 2025-05-14 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia (NCT06916793) | Chong Kun Dang Pharmaceutical | 2025-04-30 |
| Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult Volunteers (NCT06758661) | Chong Kun Dang Pharmaceutical | 2024-11-27 |
| A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants (NCT06727396) | Chong Kun Dang Pharmaceutical | 2024-11-14 |
| Clinical Study to Evaluate the Food Effect of CKD-378 in Healthy Volunteers (NCT06709807) | Chong Kun Dang Pharmaceutical | 2024-11-08 |
| Clinical Study to Evaluate the Food Effect of CKD-383 0.5/10/1000mg in Healthy Volunteers (NCT06695572) | Chong Kun Dang Pharmaceutical | 2024-11-06 |
| Clinical Study to Evaluate the Food Effect of CKD-383 0.5/25/1000mg in Healthy Volunteers (NCT06695598) | Chong Kun Dang Pharmaceutical | 2024-11-06 |
| A Clinical Trial to Evaluate the Food Effect of CKD-379 (NCT06652971) | Chong Kun Dang Pharmaceutical | 2024-11-05 |
| Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A (NCT06643819) | Chong Kun Dang Pharmaceutical | 2024-10-14 |
| To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers (NCT06492655) | Chong Kun Dang Pharmaceutical | 2024-07-04 |
| Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State. (NCT06483243) | Chong Kun Dang Pharmaceutical | 2024-04-04 |
| Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D956 in Healthy Adults (NCT06281132) | Chong Kun Dang Pharmaceutical | 2024-03-22 |
| Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes (NCT06838286) | Chong Kun Dang Pharmaceutical | 2024-03-16 |
| A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6) (NCT06112678) | Chong Kun Dang Pharmaceutical | 2024-01-04 |
| A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379 (NCT06204107) | Chong Kun Dang Pharmaceutical | 2023-11-21 |
| MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients (NCT06044493) | Chong Kun Dang Pharmaceutical | 2023-11-14 |
| A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846 (NCT06110923) | Chong Kun Dang Pharmaceutical | 2023-11-13 |
| A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2) (NCT06088017) | Chong Kun Dang Pharmaceutical | 2023-10-23 |
| Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy (NCT06121518) | Chong Kun Dang Pharmaceutical | 2023-07-31 |
| A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg (NCT05698043) | Chong Kun Dang Pharmaceutical | 2023-07-17 |
| Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029 (NCT05897216) | Chong Kun Dang Pharmaceutical | 2023-07-14 |
| A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of D745, D759, and D150 (NCT05928637) | Chong Kun Dang Pharmaceutical | 2023-07-10 |
| A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828 20/1.25mg (NCT05881707) | Chong Kun Dang Pharmaceutical | 2023-07-04 |
| Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy (NCT05931224) | Chong Kun Dang Pharmaceutical | 2023-06-28 |
| Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D958 in Healthy Adults (NCT05921435) | Chong Kun Dang Pharmaceutical | 2023-06-20 |
| Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150, D029 in Healthy Adults (NCT05881213) | Chong Kun Dang Pharmaceutical | 2023-06-01 |
| A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome (NCT05843162) | Chong Kun Dang Pharmaceutical | 2023-06-01 |
| Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150 (NCT05816759) | Chong Kun Dang Pharmaceutical | 2023-05-26 |
| A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828 (NCT05834595) | Chong Kun Dang Pharmaceutical | 2023-05-02 |
| A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5) (NCT05749861) | Chong Kun Dang Pharmaceutical | 2023-04-22 |
| Efficacy and Safety of Telmisartan Compared With Losartan (NCT06431477) | Chong Kun Dang Pharmaceutical | 2023-04-19 |
| A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378 (NCT05741437) | Chong Kun Dang Pharmaceutical | 2023-04-11 |
| Pharmacokinetics and Safety/Tolerability of CKD-379 (NCT05719155) | Chong Kun Dang Pharmaceutical | 2023-02-27 |
| Clinical Study to Evaluate Pharmacokinetic Profiles and Safety of CKD-387 Under Fasting Condition (NCT05673369) | Chong Kun Dang Pharmaceutical | 2023-02-01 |
| A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391 (NCT05634447) | Chong Kun Dang Pharmaceutical | 2022-12-20 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia (NCT05677438) | Chong Kun Dang Pharmaceutical | 2022-12-20 |
| Efficacy and Safety of EsoDuo® (NCT06430047) | Chong Kun Dang Pharmaceutical | 2022-11-25 |
| A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia (NCT05657574) | Chong Kun Dang Pharmaceutical | 2022-11-24 |
| The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A (NCT05587699) | Chong Kun Dang Pharmaceutical | 2022-11-15 |
| Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-341 in Healthy Subjects (NCT05571813) | Chong Kun Dang Pharmaceutical | 2022-11-02 |
| Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects (NCT05544214) | Chong Kun Dang Pharmaceutical | 2022-10-21 |
| The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes (NCT05566028) | Chong Kun Dang Pharmaceutical | 2022-10-12 |
| Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348 (NCT05549401) | Chong Kun Dang Pharmaceutical | 2022-09-29 |
| Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy (NCT05526703) | Chong Kun Dang Pharmaceutical | 2022-09-28 |
| Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions (NCT05552495) | Chong Kun Dang Pharmaceutical | 2022-09-23 |
| Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fed Conditions (NCT06399068) | Chong Kun Dang Pharmaceutical | 2022-09-19 |
| Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fasting Conditions (NCT06399055) | Chong Kun Dang Pharmaceutical | 2022-09-16 |
| Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-828 in Healthy Subjects (NCT05540912) | Chong Kun Dang Pharmaceutical | 2022-09-15 |
| A Study to Evaluate the Relative Bioavailability of Formulations of CKD-510 and to Assess the Effect of Food on the CKD-510 Tablet Formulation in Healthy Subjects (NCT05526742) | Chong Kun Dang Pharmaceutical | 2022-08-24 |
| Pharmacokinetics and Safety/Tolerability Profile of CKD-379 (NCT05452525) | Chong Kun Dang Pharmaceutical | 2022-07-26 |
| Study to Evaluate the Food Effect on Pharmacokinetics Profile and Safety of CKD-393 (NCT05274880) | Chong Kun Dang Pharmaceutical | 2022-06-21 |
| Study to Evaluate the Safety and Pharmacokinetics of CKD-331 (NCT05335044) | Chong Kun Dang Pharmaceutical | 2022-05-31 |
| A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions (NCT05347576) | Chong Kun Dang Pharmaceutical | 2022-04-21 |
| A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg (NCT05245084) | Chong Kun Dang Pharmaceutical | 2022-03-15 |
| CKD-506 Drug-Drug Interaction Study in Healthy Male Subjects (NCT05238948) | Chong Kun Dang Pharmaceutical | 2022-02-28 |
| A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3) (NCT05192356) | Chong Kun Dang Pharmaceutical | 2022-02-23 |
| Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930 (NCT05207761) | Chong Kun Dang Pharmaceutical | 2022-01-19 |
| Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects (NCT05189288) | Chong Kun Dang Pharmaceutical | 2022-01-14 |
| Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393 (NCT05113693) | Chong Kun Dang Pharmaceutical | 2021-11-25 |
| Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients (NCT05193565) | Chong Kun Dang Pharmaceutical | 2021-11-19 |
| Study to Evaluate the Safety and Pharmacokinetics of CKD-349 in Healthy Adult Volunteers (NCT05089279) | Chong Kun Dang Pharmaceutical | 2021-11-03 |
| A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects (NCT05108038) | Chong Kun Dang Pharmaceutical | 2021-10-07 |
| A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment (NCT05041790) | Chong Kun Dang Pharmaceutical | 2021-09-30 |
| A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg (NCT04987970) | Chong Kun Dang Pharmaceutical | 2021-09-12 |
| A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients (NCT05050604) | Chong Kun Dang Pharmaceutical | 2021-09-01 |
| Clinical Study to Compare the Pharmacokinetics and Safety of D113 With CKD-349 in Healthy Volunteers (NCT04952506) | Chong Kun Dang Pharmaceutical | 2021-07-19 |
| Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 (NCT04871646) | Chong Kun Dang Pharmaceutical | 2021-06-30 |
| A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2) (NCT04883658) | Chong Kun Dang Pharmaceutical | 2021-06-04 |
| Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions (NCT04906798) | Chong Kun Dang Pharmaceutical | 2021-06-04 |
| Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions (NCT04906785) | Chong Kun Dang Pharmaceutical | 2021-06-04 |
| Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg (NCT04869800) | Chong Kun Dang Pharmaceutical | 2021-05-27 |
| A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers (NCT04867200) | Chong Kun Dang Pharmaceutical | 2021-04-27 |
| A Study to Investigate the Effect of Food on the PK, PD of CKD-381 in Healthy Volunteers (NCT04830930) | Chong Kun Dang Pharmaceutical | 2021-04-21 |
| A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383. (NCT04810676) | Chong Kun Dang Pharmaceutical | 2021-04-16 |
| The Safety and Pharmacokinetic/Pharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1 (NCT04840745) | Chong Kun Dang Pharmaceutical | 2021-04-01 |
| A Study to Investigate the PK and Safety of CKD-393 (NCT04768673) | Chong Kun Dang Pharmaceutical | 2021-03-26 |
| Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients (NCT04867720) | Chong Kun Dang Pharmaceutical | 2021-03-16 |
| A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) (NCT04694989) | Chong Kun Dang Pharmaceutical | 2021-02-20 |
| A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386 (NCT04673864) | Chong Kun Dang Pharmaceutical | 2021-01-17 |
| A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348 (NCT04660370) | Chong Kun Dang Pharmaceutical | 2021-01-09 |
| Efficacy and Safety of Sirolimus Plus CNI Compared With MMF Plus CNI in ABO-i Kidney Transplant Recipients. (NCT04700709) | Chong Kun Dang Pharmaceutical | 2021-01-01 |
| A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 (NCT04673695) | Chong Kun Dang Pharmaceutical | 2020-11-13 |
| Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers (NCT04611932) | Chong Kun Dang Pharmaceutical | 2020-11-11 |
| A Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of CKD-333 or Co-administration of CKD-333 and D085 in Healthy Volunteers (NCT04627207) | Chong Kun Dang Pharmaceutical | 2020-11-01 |
| Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions (NCT04678388) | Chong Kun Dang Pharmaceutical | 2020-10-29 |
| Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions (NCT04651881) | Chong Kun Dang Pharmaceutical | 2020-10-27 |
| A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348 (NCT04587206) | Chong Kun Dang Pharmaceutical | 2020-10-15 |
| A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects (NCT04703374) | Chong Kun Dang Pharmaceutical | 2020-09-25 |
| A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia (NCT04623021) | Chong Kun Dang Pharmaceutical | 2020-09-25 |